PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33931597-0	2021	GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.	Sorafenib	51-60	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	Mus musculus	0-5	
33931597-5	2021	This study aimed to investigate the role and underlying molecular mechanisms of GSTZ1 in sorafenib-induced ferroptosis in HCC.	Sorafenib	89-98	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	Mus musculus	80-85	
33931597-6	2021	GSTZ1 was significantly downregulated in sorafenib-resistant hepatoma cells.	Sorafenib	41-50	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	Mus musculus	0-5	
33931597-7	2021	Mechanistically, GSTZ1 depletion enhanced the activation of the NRF2 pathway and increased the glutathione peroxidase 4 (GPX4) level, thereby suppressing sorafenib-induced ferroptosis.	Sorafenib	154-163	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	Mus musculus	17-22	
33931597-8	2021	The combination of sorafenib and RSL3, a GPX4 inhibitor, significantly inhibited GSTZ1-deficient cell viability and promoted ferroptosis and increased ectopic iron and lipid peroxides.	Sorafenib	19-28	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	Mus musculus	81-86	
33931597-9	2021	In vivo, the combination of sorafenib and RSL3 had a synergic therapeutic effect on HCC progression in Gstz1-/- mice.	Sorafenib	28-37	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	Mus musculus	103-108	
33931597-10	2021	In conclusion, this finding demonstrates that GSTZ1 enhanced sorafenib-induced ferroptosis by inhibiting the NRF2/GPX4 axis in HCC cells.	Sorafenib	61-70	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	Mus musculus	46-51